Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy

PD-1 pathway and its clinical application: A 20 year journey after discovery of the complete human PD - 1 gene

(2018) Kristin Nicole Berger et al.   GENE

Cross-Cohort Analysis Identifies a TEAD4–MYCN Positive Feedback Loop as the Core Regulatory Element of High-Risk Neuroblastoma

(2018) Presha Rajbhandari et al.   Cancer Discovery

Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas

(2018) Franz X. Schaub et al.   Cell Systems

Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers

(2018) Edina Wang et al.   ONCOGENE

Biophysical characterization of the b-HLH-LZ of ΔMax, an alternatively spliced isoform of Max found in tumor cells: Towards the validation of a tumor suppressor role for the Max homodimers

(2017) Loïka Maltais et al.   PLoS One

Cell-Penetrating Peptides: From Basic Research to Clinics

(2017) Giulia Guidotti et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

MYC Deregulation in Primary Human Cancers

(2017) Manpreet Kalkat et al.   Genes

OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors

(2016) L A Jung et al.   ONCOGENE

MYC regulates the antitumor immune response through CD47 and PD-L1

(2016) S. C. Casey et al.   SCIENCE

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation

(2016) Francesco Paolo Fiorentino et al.   Oncotarget

c-Myc targeted regulators of cell metabolism in a transgenic mouse model of papillary lung adenocarcinoma

(2016) Yari Ciribilli et al.   Oncotarget

Small-molecule inhibitors of the Myc oncoprotein

(2015) Steven Fletcher et al.   Biochimica et Biophysica Acta-Gene Regulatory Mechanisms

c-MYC Copy-Number Gain Is an Independent Prognostic Factor in Patients with Colorectal Cancer

(2015) Kyu Sang Lee et al.   PLoS One

Myc inhibition is effective against glioma and reveals a role for Myc in proficient mitosis

(2014) Daniela Annibali et al.   Nature Communications

Therapeutic Strategies to Inhibit MYC

(2014) M. R. McKeown et al.   Cold Spring Harbor Perspectives in Medicine

An Overview of MYC and Its Interactome

(2014) M. Conacci-Sorrell et al.   Cold Spring Harbor Perspectives in Medicine

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non-Small Cell Lung Cancer

(2013) T. Shimamura et al.   CLINICAL CANCER RESEARCH

Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice

(2013) L. Soucek et al.   GENES & DEVELOPMENT

MYC-y mice: From tumour initiation to therapeutic targeting of endogenous MYC

(2013) Jennifer P. Morton et al.   Molecular Oncology

Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells

(2013) Cosimo Commisso et al.   NATURE

ATF4 Regulates MYC-Mediated Neuroblastoma Cell Death upon Glutamine Deprivation

(2012) Guoliang Qing et al.   CANCER CELL

MYC on the Path to Cancer

(2012) Chi V. Dang   CELL

siRNA and pharmacological inhibition of endocytic pathways to characterize the differential role of macropinocytosis and the actin cytoskeleton on cellular uptake of dextran and cationic cell penetrating peptides octaarginine (R8) and HIV-Tat

(2012) M. Al Soraj et al.   JOURNAL OF CONTROLLED RELEASE

Cell entry of cell penetrating peptides: tales of tails wagging dogs

(2012) Arwyn T. Jones et al.   JOURNAL OF CONTROLLED RELEASE

The Max b-HLH-LZ Can Transduce into Cells and Inhibit c-Myc Transcriptional Activities

(2012) Martin Montagne et al.   PLoS One

Cell-penetrating peptides: breaking through to the other side

(2012) Erez Koren et al.   TRENDS IN MOLECULAR MEDICINE

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Tumor microenvironment: becoming sick of Myc

(2011) Jonathan R. Whitfield et al.   CELLULAR AND MOLECULAR LIFE SCIENCES

Endogenous Myc maintains the tumor microenvironment

(2011) N. M. Sodir et al.   GENES & DEVELOPMENT

Addicted to Myc--but why?

(2011) B. von Eyss et al.   GENES & DEVELOPMENT

The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy

(2011) Mauro Savino et al.   PLoS One

c-Myc Regulates Transcriptional Pause Release

(2010) Peter B. Rahl et al.   CELL

MYC Amplification as a Prognostic Marker of Early-Stage Lung Adenocarcinoma Identified by Whole Genome Copy Number Analysis

(2010) Reika Iwakawa et al.   CLINICAL CANCER RESEARCH

MYC and EIF3H Coamplification Significantly Improve Response and Survival of Non-small Cell Lung Cancer Patients (NSCLC) Treated with Gefitinib

(2010) Federico Cappuzzo et al.   Journal of Thoracic Oncology

MYC regulation of a “poor-prognosis” metastatic cancer cell state

(2010) Anita Wolfer et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Max homodimeric b-HLH-LZ significantly interferes with the specific heterodimerization between the c-Myc and Max b-HLH-LZ in absence of DNA: a quantitative analysis

(2009) François-Olivier McDuff et al.   JOURNAL OF MOLECULAR RECOGNITION

Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery

(2008) Vladimir P. Torchilin   BIOPOLYMERS

Modelling Myc inhibition as a cancer therapy

(2008) Laura Soucek et al.   NATURE

N-myc augments death and attenuates protective effects of Bcl-2 in trophically stressed neuroblastoma cells

(2008) A Ushmorov et al.   ONCOGENE